Cysteine is a sulfur-containing amino acid that is the central intermediate of the transsulfuration pathway — the pathway by which the sulfur from methionine is transferred to cysteine, and from cysteine to the other sulfur-containing compounds that are essential for human health, including glutathione, taurine, coenzyme A, and the iron-sulfur clusters of the mitochondrial electron transport chain. Cysteine is classified as a semi-essential amino acid — it can be synthesised from methionine via the transsulfuration pathway, but it is also required in the diet, particularly during periods of rapid growth, during recovery from illness, and during ageing, when the demand for cysteine may exceed the capacity of the transsulfuration pathway to supply it. The dual origin of cysteine (from diet and from transsulfuration) makes cysteine metabolism one of the most important regulatory nodes in amino acid metabolism, and its dysregulation is implicated in some of the most common chronic diseases of modern civilisation, including cardiovascular disease, neurodegeneration, and the metabolic dysfunction that characterises diabetes and obesity.
The CBS and CGL Enzymes
The transsulfuration pathway is initiated by the enzyme cystathionine beta-synthase (CBS), which condenses homocysteine with serine to form cystathionine. CBS is one of the most important regulatory enzymes in sulfur amino acid metabolism — it is allosterically activated by S-adenosylmethionine (SAM), the primary methyl donor in the body, which means that when SAM levels are high (as after a meal rich in methionine), CBS is activated and the transsulfuration pathway is engaged, converting the excess methionine sulfur to cysteine. The second step of the transsulfuration pathway is catalysed by cystathionine gamma-lyase (CGL), which cleaves cystathionine to form cysteine, alpha-ketobutyrate, and ammonia. Both CBS and CGL require vitamin B6 (as pyridoxal phosphate, PLP) as a cofactor, and vitamin B6 deficiency impairs the transsulfuration pathway, leading to the accumulation of homocysteine and to the clinical syndrome of hyperhomocysteinemia.
The clinical importance of the transsulfuration pathway is underscored by the genetic disorders that affect it. CBS deficiency (which is the most common cause of hyperhomocysteinemia in children and young adults) produces markedly elevated homocysteine levels, homocystinuria, and a clinical syndrome that is characterised by ectopia lentis (dislocation of the lens of the eye), intellectual disability, thromboembolic complications (including deep vein thrombosis, pulmonary embolism, and stroke), and osteoporosis. The treatment of CBS deficiency involves dietary methionine restriction (to reduce the homocysteine burden), vitamin B6 supplementation (to activate the residual CBS enzyme, which in some mutations retains partial B6 responsiveness), and betaine supplementation (to provide an alternative pathway for the remethylation of homocysteine to methionine).
Cysteine and Glutathione Synthesis
Cysteine is the rate-limiting substrate for glutathione synthesis — the glutathione synthetase enzyme requires cysteine as one of its three substrates (along with glutamate and glycine), and when cysteine availability is low, glutathione synthesis is limited by the cysteine supply. Glutathione is the most abundant intracellular antioxidant in human cells and is the primary defence against reactive oxygen species, electrophilic toxins, and the inflammatory mediators that accumulate in chronic disease. The clinical consequences of glutathione depletion are broad — in the liver, glutathione depletion impairs the Phase II detoxification system; in the brain, it contributes to the neuronal death that characterises neurodegenerative diseases; in the cardiovascular system, it contributes to the endothelial dysfunction that underlies atherosclerosis; and in the pancreatic beta cells, it contributes to the oxidative damage that leads to the beta cell failure that characterises type 2 diabetes.
Practical Application
For general cysteine and transsulfuration support, the evidence-based approach is to ensure adequate methionine intake from dietary protein (methionine is abundant in animal proteins and in legumes), to maintain adequate vitamin B6 status for the CBS and CGL enzymes, and to supplement with NAC (N-acetylcysteine, at 500-1,000mg daily) when glutathione support is needed, as during recovery from illness, during intense physical training, or during exposure to toxins. NAC is rapidly deacetylated to cysteine in the liver and provides a bioavailable source of cysteine for glutathione synthesis. For comprehensive sulfur amino acid metabolism support, cysteine pairs well with the B-complex vitamins (particularly vitamin B6 and folate, which are required for the transsulfuration pathway and for the remethylation of homocysteine), with selenium (which is required for the glutathione peroxidase enzymes that use GSH as a cofactor and which protects the liver from oxidative damage), with zinc (which is required for the function of the superoxide dismutase enzymes that are part of the antioxidant defence system), and with the omega-3 fatty acids (which have anti-inflammatory effects that reduce the demand for glutathione in the inflammatory response).
Leave a Reply